Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

608
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
608
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

288
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
288
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

56
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.2K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

664
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
664

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Self-esteem and Quality of Life in Men Undergoing Chemical Peeling.

Acta dermatovenerologica Croatica : ADC·2025
Same author

Atorvastatin attenuates the expression of damage-associated molecular patterns and inflammatory cytokines in patients with psoriasis.

Pharmacological reports : PR·2025
Same author

Melasma: A Clinical and Epidemiological Single-Group Observational Study in the Greek Population.

Dermatology and therapy·2024
Same author

Amicrobial pustulosis of the folds: long-term remission achieved with low dose dapsone and topical pimecrolimus.

Dermatology online journal·2023
Same author

Clinical characteristics and treatment options for multifocal hyperhidrosis in a single-centre real-world population.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Immune Classification of Hidradenitis Suppurativa: Modulation by Secukinumab.

The Journal of investigative dermatology·2023

Related Experiment Video

Updated: Mar 2, 2026

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid
04:12

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

1.7K

Methotrexate: an effective monotherapy for refractory generalized morphea.

Eftychia Platsidaki1, Vassiliki Tzanetakou1, Anargyros Kouris1

  • 1Department of Dermatology and Venereology, Andreas Syggros Hospital, University of Athens, Athens, Greece.

Clinical, Cosmetic and Investigational Dermatology
|May 17, 2017
PubMed
Summary
This summary is machine-generated.

Methotrexate (MTX) effectively treated refractory generalized morphea in adults. Most patients showed significant improvement with minimal adverse events, establishing MTX as a safe and viable monotherapy option for this condition.

Keywords:
adultsgeneralized morpheamethotrexate

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.6K
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.4K

Related Experiment Videos

Last Updated: Mar 2, 2026

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid
04:12

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

1.7K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.6K
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.4K

Area of Science:

  • Dermatology
  • Rheumatology
  • Immunology

Background:

  • Morphea is an inflammatory skin condition marked by excess collagen.
  • Current treatment guidelines for morphea lack consistency.
  • This study focuses on methotrexate (MTX) for difficult-to-treat generalized morphea.

Purpose of the Study:

  • To assess the effectiveness of methotrexate (MTX) as a standalone treatment for generalized morphea.
  • To evaluate MTX in adult patients with morphea resistant to other therapies.

Main Methods:

  • Retrospective analysis of 20 adult patients with refractory generalized morphea.
  • Patients received 15 mg of oral methotrexate weekly.
  • Clinical outcomes and adverse events were documented.

Main Results:

  • After 12 months, 30% showed very good response, 50% good response, and 10% fair response.
  • 10% of patients did not respond to MTX treatment.
  • No serious adverse events were reported during the mean 21-month follow-up.

Conclusions:

  • Methotrexate is proven effective and well-tolerated in pediatric morphea.
  • Adult patients with generalized morphea demonstrated significant improvement with MTX monotherapy.
  • MTX monotherapy is a safe and effective option for adult generalized morphea management.